search icon
wint-img

Windtree Therapeutics Inc, Common Stock

WINT

NAQ

$0.2529

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.21M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.35M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.64
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.26 L
$14.75 H
$0.2529

About Windtree Therapeutics Inc, Common Stock

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameWINTSectorS&P500
1-Week Return-18.42%1.76%-2.5%
1-Month Return-27.74%0.33%-3.91%
3-Month Return-62.81%-8.58%-0.59%
6-Month Return-93.16%-4.26%3.45%
1-Year Return-97.62%1.27%22.31%
3-Year Return-99.98%5.33%25%
5-Year Return-100%38.09%77.23%
10-Year Return-100%102.29%188.04%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue198.00K----[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue12.69K638.00K869.00K1.06M82.00K[{"date":"2019-12-31","value":1.2,"profit":true},{"date":"2020-12-31","value":60.13,"profit":true},{"date":"2021-12-31","value":81.9,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":7.73,"profit":true}]
Gross Profit185.31K(638.00K)(869.00K)(1.06M)(82.00K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-344.28,"profit":false},{"date":"2021-12-31","value":-468.94,"profit":false},{"date":"2022-12-31","value":-572.54,"profit":false},{"date":"2023-12-31","value":-44.25,"profit":false}]
Gross Margin93.59%----[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses25.09M30.32M32.26M21.89M17.46M[{"date":"2019-12-31","value":77.78,"profit":true},{"date":"2020-12-31","value":93.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":67.85,"profit":true},{"date":"2023-12-31","value":54.11,"profit":true}]
Operating Income(24.89M)(30.32M)(77.28M)(41.33M)(17.54M)[{"date":"2019-12-31","value":-2489300000,"profit":false},{"date":"2020-12-31","value":-3031700000,"profit":false},{"date":"2021-12-31","value":-7728000000,"profit":false},{"date":"2022-12-31","value":-4133300000,"profit":false},{"date":"2023-12-31","value":-1753900000,"profit":false}]
Total Non-Operating Income/Expense(2.92M)(2.25M)(45.39M)(19.03M)(2.48M)[{"date":"2019-12-31","value":-292400000,"profit":false},{"date":"2020-12-31","value":-225200000,"profit":false},{"date":"2021-12-31","value":-4538600100,"profit":false},{"date":"2022-12-31","value":-1903000000,"profit":false},{"date":"2023-12-31","value":-247700000,"profit":false}]
Pre-Tax Income(27.48M)(32.57M)(77.62M)(40.58M)(20.29M)[{"date":"2019-12-31","value":-2747500000,"profit":false},{"date":"2020-12-31","value":-3256600000,"profit":false},{"date":"2021-12-31","value":-7762300000,"profit":false},{"date":"2022-12-31","value":-4057500000,"profit":false},{"date":"2023-12-31","value":-2029100000,"profit":false}]
Income Taxes2.39M(2.29M)(9.99M)(1.37M)(85.89K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-95.77,"profit":false},{"date":"2021-12-31","value":-418.39,"profit":false},{"date":"2022-12-31","value":-57.27,"profit":false},{"date":"2023-12-31","value":-3.6,"profit":false}]
Income After Taxes(29.86M)(30.28M)(67.64M)(39.21M)(20.21M)[{"date":"2019-12-31","value":-2986200000,"profit":false},{"date":"2020-12-31","value":-3028000000,"profit":false},{"date":"2021-12-31","value":-6763600000,"profit":false},{"date":"2022-12-31","value":-3920800000,"profit":false},{"date":"2023-12-31","value":-2020510500,"profit":false}]
Income From Continuous Operations(27.48M)(32.57M)(67.64M)(39.21M)(20.29M)[{"date":"2019-12-31","value":-2747500000,"profit":false},{"date":"2020-12-31","value":-3256600000,"profit":false},{"date":"2021-12-31","value":-6763600000,"profit":false},{"date":"2022-12-31","value":-3920800000,"profit":false},{"date":"2023-12-31","value":-2029100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(29.86M)(30.28M)(67.64M)(39.21M)(20.29M)[{"date":"2019-12-31","value":-2986200000,"profit":false},{"date":"2020-12-31","value":-3028000000,"profit":false},{"date":"2021-12-31","value":-6763600000,"profit":false},{"date":"2022-12-31","value":-3920800000,"profit":false},{"date":"2023-12-31","value":-2029100000,"profit":false}]
EPS (Diluted)-(82.49)(66.50)(43.98)(8.00)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-8249,"profit":false},{"date":"2021-12-31","value":-6650,"profit":false},{"date":"2022-12-31","value":-4398,"profit":false},{"date":"2023-12-31","value":-800,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

WINT
Cash Ratio 0.16
Current Ratio 0.27

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

WINT
ROA (LTM) -44.76%
ROE (LTM) -150.80%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

WINT
Debt Ratio Lower is generally better. Negative is bad. 0.86
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.14

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

WINT
Trailing PE NM
Forward PE 0.37
P/S (TTM) 660.53
P/B 0.52
Price/FCF NM
EV/R 706.08
EV/Ebitda 0.01
PEG NM

FAQs

What is Windtree Therapeutics Inc share price today?

Windtree Therapeutics Inc (WINT) share price today is $0.2529

Can Indians buy Windtree Therapeutics Inc shares?

Yes, Indians can buy shares of Windtree Therapeutics Inc (WINT) on Vested. To buy Windtree Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in WINT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Windtree Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Windtree Therapeutics Inc (WINT) via the Vested app. You can start investing in Windtree Therapeutics Inc (WINT) with a minimum investment of $1.

How to invest in Windtree Therapeutics Inc shares from India?

You can invest in shares of Windtree Therapeutics Inc (WINT) via Vested in three simple steps:

  • Click on Sign Up or Invest in WINT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Windtree Therapeutics Inc shares
What is Windtree Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Windtree Therapeutics Inc (WINT) is $14.75. The 52-week low price of Windtree Therapeutics Inc (WINT) is $0.26.

What is Windtree Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Windtree Therapeutics Inc (WINT) is

What is Windtree Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Windtree Therapeutics Inc (WINT) is 0.52

What is Windtree Therapeutics Inc dividend yield?

The dividend yield of Windtree Therapeutics Inc (WINT) is 0.00%

What is the Market Cap of Windtree Therapeutics Inc?

The market capitalization of Windtree Therapeutics Inc (WINT) is $2.21M

What is Windtree Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Windtree Therapeutics Inc is WINT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top